HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Hangzhou Tigermed Consulting (3347.HK/300347.CH) - More of an Investment Company than a CRO

Wuxi Biologics (2269.HK) 2021Q3 - The Strength and the Concerns Behind the New Full-Year Guidance

Pre-IPO Adlai Nortye - Insights on Pipeline and Concerns

WuXi AppTec (603259.CH/2359.HK) - The Smart Business Model

WuXi AppTec (2359.HK) - The Certainties and the Uncertainties

Pre-IPO LianBio (LIAN.US) - The Strength and the Concerns

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

<ul>
<li>Recently, <a href="https://www.smartkarma.com/entities/wuxi-apptec-co-ltd-bf4a1265-beef-48b6-b82d-29308426030f" target="_blank" data-smartkarma-citation="entities:27795:1" rel="noopener">WuXi AppTec Co. Ltd. (2359 HK)</a> released its 2021Q3 results, and the Company maintained strong growth. </li>
<li>The “reflection arc” of domestic negative policy impact as well as the increasing labor cost have begun to slowly reflect.</li>
<li>Together with other concerns that could also cast doubts on Wuxi AppTec’s outlook, investors are advised to get prepared in advance. </li>
</ul>


Recently, WuXi AppTec Co. Ltd. (2359 HK) released its 2021Q3 results, and the Company maintained strong growth. 
The “reflection arc” of domestic negative policy impact as well as the increasing labor cost have begun to slowly reflect.
Together with other concerns that could also cast doubts on Wuxi AppTec’s outlook, investors are advised to get prepared in advance. 


WuXi AppTec (2359.HK/603259.CH) 2021Q3 - Logic Change?